The Drug Discovery World Podcast
Selective Translation Regulator Inhibitors: Depriving cancer of what it needs
Apr 29, 2024
Steve Worland, CEO of eFFECTOR, discusses Selective Translation Regulator Inhibitors (STRIs) targeting 3 key genes in cancer cells, the future of cancer treatments, and the importance of pharma collaborations in drug development.
17:51
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- Selective Translation Regulator Inhibitors (STRIs) target specific proteins in oncogenic signaling for more effective cancer therapy.
- AI's transformative power lies in decoding complex biological data for personalized cancer treatments.
Deep dives
Effector's Pipeline of STRIs - A Novel Approach to Cancer Therapy
Selective translation regulator inhibitors (STRIs) present a new class of cancer therapies that target the over-production of specific proteins in oncogenic signaling. By selectively blocking this up-regulated protein synthesis without broadly inhibiting protein production, STRIs aim to overcome genetic complexity and treatment resistance commonly faced in cancer therapy. Effector's scientific founders identified this unique approach to oncogenic signaling, offering a new strategy distinct from traditional targeted therapies.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
